612 related articles for article (PubMed ID: 28557600)
1. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing-based panel testing for myeloid neoplasms.
Kuo FC; Dong F
Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
[TBL] [Abstract][Full Text] [Related]
3. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
[TBL] [Abstract][Full Text] [Related]
4. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
[TBL] [Abstract][Full Text] [Related]
5. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Oncomine
Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
[TBL] [Abstract][Full Text] [Related]
7. Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.
Izevbaye I; Liang LY; Mather C; El-Hallani S; Maglantay R; Saini L
J Mol Diagn; 2020 Feb; 22(2):208-219. PubMed ID: 31751678
[TBL] [Abstract][Full Text] [Related]
8. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
[TBL] [Abstract][Full Text] [Related]
9. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
[TBL] [Abstract][Full Text] [Related]
10. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
Northrup V; Maybank A; Carson N; Rahmeh T
Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888
[TBL] [Abstract][Full Text] [Related]
11. Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing.
Shen W; Paxton CN; Szankasi P; Longhurst M; Schumacher JA; Frizzell KA; Sorrells SM; Clayton AL; Jattani RP; Patel JL; Toydemir R; Kelley TW; Xu X
J Clin Pathol; 2018 Apr; 71(4):372-378. PubMed ID: 29197855
[TBL] [Abstract][Full Text] [Related]
12. Performance evaluation of the next-generation sequencing approach for molecular diagnosis of hereditary hearing loss.
Sivakumaran TA; Husami A; Kissell D; Zhang W; Keddache M; Black AP; Tinkle BT; Greinwald JH; Zhang K
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1007-16. PubMed ID: 23525850
[TBL] [Abstract][Full Text] [Related]
13. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
[TBL] [Abstract][Full Text] [Related]
14. Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms.
Park J; Kim HS; Lee JM; Jung J; Kang D; Choi H; Lee GD; Son J; Park S; Cho BS; Kim HJ; Kim S; Lee JW; Chung NG; Cho B; Zhang H; Khazanov NA; Choi J; Jung JW; Kim Y; Kim M
Mol Diagn Ther; 2020 Oct; 24(5):579-592. PubMed ID: 32676933
[TBL] [Abstract][Full Text] [Related]
15. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
[TBL] [Abstract][Full Text] [Related]
16. Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies.
Levy MA; Santos S; Kerkhof J; Stuart A; Aref-Eshghi E; Guo F; Hedley B; Wong H; Rauh M; Feilotter H; Berardi P; Semenuk L; Yang P; Knoll J; Ainsworth P; McLachlin CM; Chin-Yee I; Kovacs M; Deotare U; Lazo-Langner A; Hsia C; Keeney M; Xenocostas A; Howlett C; Lin H; Sadikovic B
Eur J Haematol; 2019 Sep; 103(3):178-189. PubMed ID: 31177553
[TBL] [Abstract][Full Text] [Related]
17. Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines.
Leung B; Aung H; Nandini A; Abdulrasool G; Lau C; Seymour L
J Mol Diagn; 2024 May; 26(5):399-412. PubMed ID: 38367765
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms.
Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Jones K; Ahluwalia M; Okechukwu N; Savage NM; Kota V; Rojiani AM; Kolhe R
PLoS One; 2020; 15(10):e0240976. PubMed ID: 33075099
[TBL] [Abstract][Full Text] [Related]
19. The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.
Maierhofer A; Mehta N; Chisholm RA; Hutter S; Baer C; Nadarajah N; Pohlkamp C; Thompson ER; James PA; Kern W; Haferlach C; Meggendorfer M; Haferlach T; Blombery P
Blood Adv; 2023 Dec; 7(23):7346-7357. PubMed ID: 37874914
[TBL] [Abstract][Full Text] [Related]
20. Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies.
Waldmüller S; Schroeder C; Sturm M; Scheffold T; Imbrich K; Junker S; Frische C; Hofbeck M; Bauer P; Bonin M; Gawaz M; Gramlich M
Mol Cell Probes; 2015 Oct; 29(5):308-14. PubMed ID: 25979592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
